Sickle Cell Disease Diagnosis Market to Reach USD 7.9 Billion by 2028

Vantage Market Research

Nov 12, 2021

According to analysts at Vantage Market Research, the sickle cell disease diagnosis market is expected to reach USD 7.9 Billion by 2028, growing at a CAGR of 7.8% from 2021 to 2028.

As the number of individuals with sickle cell disease explains the increase in demand for sickle cell disease diagnosis markets overall the globe for better treatment and condition effectively. The United States Food and Drug Administration (USFDA) approve new drugs to control pain in adults and SCD. This new drug is expected to support the company’s commitment to combat SCD and would help in expanding the sickle cell disease diagnosis market. The rising occurrence of sickle cell disease, particularly in Africa is augmenting the market growth. New Product Development is also helping in driving the market growth.

Sickle Cell Disease Diagnosis Preview

  • The sickle cell disease diagnosis segment is projected to expand at the fastest CAGR exceeding 25% over the forecast period owing to the increasing adoption in testing and diagnosis for sickle cell disease
  • The adult diagnosis market segment held a market share of around 60% in 2020. This share is further expected to grow as more and more individuals are being diagnosed with sickle cell disease.
  • Europe region is expected to expand at a CAGR of over 29% from 2021 to 2028. This surge is attributed to the rising in medical treatment and better facilities in the diagnosis field.

Asia Pacific region is poised to record the highest CAGR, owing to the increasing number of cases of individual-related sickle cell disease. Countries, such as India, China, and Japan, coupled with the growth of the region's overall robotics market. The African region is also having a high number of individual-related sickle cell diseases. However, the advent of domestic versions has brought down the prices, which is expected to drive the deployment.

Some of the key players in the surgical robotics market are AstraZeneca Plc, Baxter International Inc., bluebird bio Inc., Bristol-Myers Squibb Company, CRISPR Therapeutics, Emmaus Medical Inc., Global Blood Therapeutics Inc., GlycoMimetics Inc., Novartis AG, Pfizer Inc., and Sangamo Therapeutics, among others.  The market is comprised of a high degree of competition due to the presence of numerous key players. Manufacturers are focusing on opting for various inorganic growth strategies such as acquisitions, mergers, and geographical expansion to leverage their market share and gain a competitive advantage.